Aktie A3CQ6L DYNC SPL
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen DYNC SPL

Aktien

A3CQ6L

US2680101050

DYNS

Markt geschlossen - Nasdaq
Andere Börsenplätze
 22:30:01 03.05.2024 		% 5 Tage % 1. Jan.
0,37 USD +0,35 % Intraday Chart für DYNC SPL +27,59 % -95,07 %
2022 Senti Biosciences schließt Unternehmenszusammenschluss ab und wird am Donnerstag den Handel an der Nasdaq aufnehmen MT
2022 Senti Biosciences, Inc. hat die Übernahme von Dynamics Special Purpose Corp. (NasdaqCM:DYNS) von einer Gruppe von Aktionären in einer Reverse-Merger-Transaktion abgeschlossen. CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
DYNC SPL : SENTI BIOSCIENCES, INC. INDEX TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Form 8-K
Senti Biosciences Completes Business Combination, Will Begin Trading on Nasdaq Thursday
DYNC SPL : Senti Bio Debuts as Publicly Traded Company Focused on Developing Next-Generation Cell and Gene Therapies Engineered with Gene Circuits - Form 8-K
DYNAMICS SPECIAL PURPOSE CORP. : Other Events, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
Senti Bio Debuts as Publicly Traded Company Focused on Developing Next-Generation Cell and Gene Therapies Engineered with Gene Circuits
Dynamics Special Purpose Corp.(NasdaqCM:DYNS) dropped from NASDAQ Composite Index
Senti Biosciences, Inc. completed the acquisition of Dynamics Special Purpose Corp. from a group of shareholders in a reverse merger transaction.
DYNAMICS SPECIAL PURPOSE CORP. : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders, Other Events (form 8-K)
Dynamics Special Purpose Corp. has Changed its Name to Senti Biosciences, Inc
Dynamics Special Purpose Corp. Approves Board Elections
Dynamics Special Purpose : Senti Bio Names Dr. Kanya Rajangam to Newly Created Position of Chief Medical and Development Officer - Form 8-K
DYNAMICS SPECIAL PURPOSE CORP. : Other Events, Financial Statements and Exhibits (form 8-K)
Leaps by Bayer led Series B investment in Senti Bio in 2021; Additional Convertible Note financing expands committed capital to PIPE investment associated with previously announced Business Combination Agreement with DYNS - - DYNS announces effectiveness of registration statement on Form S-4 - - Meeting of DYNS stockholders to approve proposed business combination scheduled for Tuesday, June 7, 2022 at 10:00 a.m. ET - Form 8-K
DYNAMICS SPECIAL PURPOSE CORP. : Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
DYNAMICS SPECIAL PURPOSE CORP. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
Dynamics Special Purpose Corp. Reports Earnings Results for the First Quarter Ended March 31, 2022
DYNAMICS SPECIAL PURPOSE CORP. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)
SPACs splash the cash to salvage deals as market unravels
DYNAMICS SPECIAL PURPOSE CORP. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)
Dynamics Special Purpose Corp. Reports Earnings Results for the Ten Months Ended December 31, 2021
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A3CQ6L Aktie
  4. Nachrichten DYNC SPL
  5. Andere Sprachen